Literature DB >> 26651341

Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Elizabeth Head1, Ira T Lott, Donna M Wilcock, Cynthia A Lemere.   

Abstract

Chromosome 21, triplicated in Down Syndrome, contains several genes that are thought to play a critical role in the development of AD neuropathology. The overexpression of the gene for the amyloid precursor protein (APP), on chromosome 21, leads to early onset beta-amyloid (Aβ) plaques in DS. In addition to Aβ accumulation, middle-aged people with DS develop neurofibrillary tangles, cerebrovascular pathology, white matter pathology, oxidative damage, neuroinflammation and neuron loss. There is also evidence of potential compensatory responses in DS that benefit the brain and delay the onset of dementia after there is sufficient neuropathology for a diagnosis of AD. This review describes some of the existing literature and also highlights gaps in our knowledge regarding AD neuropathology in DS. It will be critical in the future to develop networked brain banks with standardized collection procedures to fully characterize the regional and temporal pathological events associated with aging in DS. As more information is acquired regarding AD evolution in DS, there will be opportunities to develop interventions that are age-appropriate to delay AD in DS.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26651341      PMCID: PMC4948181          DOI: 10.2174/1567205012666151020114607

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  155 in total

Review 1.  Down syndrome and beta-amyloid deposition.

Authors:  Elizabeth Head; Ira T Lott
Journal:  Curr Opin Neurol       Date:  2004-04       Impact factor: 5.710

2.  Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome.

Authors:  Anne M Cataldo; Suzana Petanceska; Nicole B Terio; Corrinne M Peterhoff; Robert Durham; Marc Mercken; Pankaj D Mehta; Joseph Buxbaum; Vahram Haroutunian; Ralph A Nixon
Journal:  Neurobiol Aging       Date:  2004 Nov-Dec       Impact factor: 4.673

3.  Precocious aging and dementia in patients with Down's syndrome.

Authors:  K Wisniewski; J Howe; D G Williams; H M Wisniewski
Journal:  Biol Psychiatry       Date:  1978-10       Impact factor: 13.382

4.  Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome.

Authors:  Antonia M W Coppus; Maaike Schuur; Jeanet Vergeer; A Cecile J W Janssens; Ben A Oostra; Marcel M Verbeek; Cornelia M van Duijn
Journal:  Neurobiol Aging       Date:  2011-09-29       Impact factor: 4.673

5.  Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice.

Authors:  O Wirths; G Multhaup; C Czech; V Blanchard; S Moussaoui; G Tremp; L Pradier; K Beyreuther; T A Bayer
Journal:  Neurosci Lett       Date:  2001-06-22       Impact factor: 3.046

Review 6.  Regulation of APP cleavage by alpha-, beta- and gamma-secretases.

Authors:  J Nunan; D H Small
Journal:  FEBS Lett       Date:  2000-10-13       Impact factor: 4.124

7.  Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome.

Authors:  V P Prasher; S G Sajith; P Mehta; W B Zigman; N Schupf
Journal:  Int J Geriatr Psychiatry       Date:  2010-02       Impact factor: 3.485

Review 8.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

9.  Upregulation of phosphorylated alphaB-crystallin in the brain of children and young adults with Down syndrome.

Authors:  Sonia Palminiello; Katarzyna Jarząbek; Kulbir Kaur; Marius Walus; Ausma Rabe; Giorgio Albertini; Adam A Golabek; Elizabeth Kida
Journal:  Brain Res       Date:  2009-03-09       Impact factor: 3.252

10.  Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein.

Authors:  M F Knauer; B Soreghan; D Burdick; J Kosmoski; C G Glabe
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

View more
  82 in total

1.  The Link between Alzheimer's Disease and Down Syndrome. A Historical Perspective.

Authors:  Ahmad Salehi; J Wesson Ashford; Elliott J Mufson
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

Review 2.  Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors.

Authors:  Chanung Wang; David M Holtzman
Journal:  Neuropsychopharmacology       Date:  2019-08-13       Impact factor: 7.853

Review 3.  Neuropathological correlates of amyloid PET imaging in Down syndrome.

Authors:  Eric E Abrahamson; Elizabeth Head; Ira T Lott; Benjamin L Handen; Elliott J Mufson; Bradley T Christian; William E Klunk; Milos D Ikonomovic
Journal:  Dev Neurobiol       Date:  2019-08-17       Impact factor: 3.964

Review 4.  Exosome release and cargo in Down syndrome.

Authors:  Eric D Hamlett; Angela LaRosa; Elliott J Mufson; Juan Fortea; Aurélie Ledreux; Ann-Charlotte Granholm
Journal:  Dev Neurobiol       Date:  2019-08-06       Impact factor: 3.964

5.  Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.

Authors:  Alexander M Kleschevnikov; Jessica Yu; Jeesun Kim; Larisa V Lysenko; Zheng Zeng; Y Eugene Yu; William C Mobley
Journal:  Neurobiol Dis       Date:  2017-03-22       Impact factor: 5.996

6.  Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia.

Authors:  Sylvia E Perez; Jennifer C Miguel; Bin He; Michael Malek-Ahmadi; Eric E Abrahamson; Milos D Ikonomovic; Ira Lott; Eric Doran; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson
Journal:  Acta Neuropathol       Date:  2019-02-07       Impact factor: 17.088

7.  Comparative analysis of the DYRK1A-SRSF6-TNNT2 pathway in myocardial tissue from individuals with and without Down syndrome.

Authors:  Adolfo Quiñones-Lombraña; Javier G Blanco
Journal:  Exp Mol Pathol       Date:  2019-06-12       Impact factor: 3.362

8.  Comparison of longitudinal Aβ in nondemented elderly and Down syndrome.

Authors:  Dana L Tudorascu; Stewart J Anderson; Davneet S Minhas; Zheming Yu; Diane Comer; Patrick Lao; Sigan Hartley; Charles M Laymon; Beth E Snitz; Brian J Lopresti; Sterling Johnson; Julie C Price; Chester A Mathis; Howard J Aizenstein; William E Klunk; Benjamin L Handen; Brad T Christian; Ann D Cohen
Journal:  Neurobiol Aging       Date:  2018-09-27       Impact factor: 4.673

9.  Microbleeds and Cerebral Amyloid Angiopathy in the Brains of People with Down Syndrome with Alzheimer's Disease.

Authors:  Alex M Helman; Morgan Siever; Katie L McCarty; Ira T Lott; Eric Doran; Erin L Abner; Frederick A Schmitt; Elizabeth Head
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 10.  Polyubiquitinylation Profile in Down Syndrome Brain Before and After the Development of Alzheimer Neuropathology.

Authors:  Antonella Tramutola; Fabio Di Domenico; Eugenio Barone; Andrea Arena; Alessandra Giorgi; Laura di Francesco; Maria Eugenia Schininà; Raffaella Coccia; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Antioxid Redox Signal       Date:  2016-10-26       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.